Tool
Supplement comparison tool
Pick up to 4 knowledge base entries and compare their dosage, price, evidence strength and ratings side by side — you can save or share a link to your selection.
Add to comparison (2/4)
| Category | Leki | Leki |
| Evidence strength | Strong evidence | Strong evidence |
| Evidence Score | 4/5 | 4/5 |
| User rating | 4.5 (83) | 4.5 (76) |
| Typical dose | Esketamine (Spravato): starting dose of 56 mg intranasally on day 1, then 56 or 84 mg twice weekly for the first 4 weeks, later once weekly or every 2 weeks during the maintenance phase, always combined with an oral antidepressant. Off-label IV ketamine: typically 0.5 mg/kg body weight over a 40-minute infusion, given as a series of several sessions (e.g. 6 sessions over 2-3 weeks) in a clinical setting. | Determined individually by a doctor, usually 500–2000 mg daily in divided doses, with meals |
| Form | Spravato — an intranasal spray containing esketamine, a prescription drug. Off-label IV ketamine — an infusion given exclusively in clinical settings by medical staff. | Oral tablets, including extended-release (XR) forms that reduce gastrointestinal discomfort |
| Average price | Jedna sesja dożylnego wlewu ketaminy w prywatnej klinice w Polsce: ok. 800–2000 zł; esketamina (Spravato) w ramach prywatnej opieki psychiatrycznej bywa droższa ze względu na koszt samego leku i wymóg certyfikowanej placówki | — |
| Monthly cost | W fazie indukcyjnej (2 podania tygodniowo) koszt miesięczny może sięgać kilku tysięcy złotych, zależnie od placówki i formy leczenia | — |
| Time to effects | The antidepressant effect can be noticeable within hours to 24 hours after the first administration, though in most patients it's short-lived after a single dose and requires a series of repeated administrations within a supervised protocol to maintain the effect during the maintenance phase. | Lowering of glycemia is usually visible within days to weeks of starting therapy and reaching the target dose. |
| Who it's for | Patients with a formal diagnosis of treatment-resistant depression who have not responded to at least two prior lines of standard pharmacological treatment | People with type 2 diabetes or prediabetes, qualified by a doctor |